Search for other papers by Janice Ser Huey Tan in
Google Scholar
PubMed
Search for other papers by Timothy Kwang Yong Tay in
Google Scholar
PubMed
Search for other papers by Enya Hui Wen Ong in
Google Scholar
PubMed
Search for other papers by Michael Fehlings in
Google Scholar
PubMed
Search for other papers by Daniel Shao-Weng Tan in
Google Scholar
PubMed
Search for other papers by Nadiah Binte Sukma in
Google Scholar
PubMed
Search for other papers by Eileen Xueqin Chen in
Google Scholar
PubMed
Search for other papers by Jen-Hwei Sng in
Google Scholar
PubMed
Search for other papers by Connie Siew Poh Yip in
Google Scholar
PubMed
Search for other papers by Kok Hing Lim in
Google Scholar
PubMed
Search for other papers by Darren Wan-Teck Lim in
Google Scholar
PubMed
Search for other papers by Narayanan Gopalakrishna Iyer in
Google Scholar
PubMed
Search for other papers by Jacqueline Siok Gek Hwang in
Google Scholar
PubMed
Search for other papers by Melvin Lee Kiang Chua in
Google Scholar
PubMed
Search for other papers by Mei-Kim Ang in
Google Scholar
PubMed
methods Patient selection Consecutive patients with newly diagnosed ATC at a single institution with ECOG ≤2, adequate organ function, no active autoimmune disease and contraindications to immunotherapy were included. Diagnosis and pathology of all
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Laura Pierotti in
Google Scholar
PubMed
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Search for other papers by Chiara Cremolini in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Antonio Chella in
Google Scholar
PubMed
Search for other papers by Andrea Antonuzzo in
Google Scholar
PubMed
Search for other papers by Daniele Sgrò in
Google Scholar
PubMed
Search for other papers by Lucia Antonangeli in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Ferruccio Santini in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
(i.e. subacute thyroiditis and type 2 amiodarone-induced thyrotoxicosis) ( 9 , 10 ), recent guidelines and expert opinion recommend no treatment for the destructive forms induced by immunotherapy, since data in this setting are lacking ( 3 , 11
Department of Medicine I, Johannes Gutenberg University Medical Center, Mainz, Germany
Search for other papers by Alan Chun Hong Lee in
Google Scholar
PubMed
Search for other papers by George J. Kahaly in
Google Scholar
PubMed
]. ATX-GD-59 Rationale and Mechanisms of Actions. Antigen-specific immunotherapy is an effective treatment for common allergic conditions, especially atopy (allergic rhinitis/conjunctivitis, asthma, atopic dermatitis) and stinging insect
Department of Nuclear Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Junyu Tong in
Google Scholar
PubMed
Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Search for other papers by Maomei Ruan in
Google Scholar
PubMed
Search for other papers by Yuchen Jin in
Google Scholar
PubMed
Search for other papers by Hao Fu in
Google Scholar
PubMed
Search for other papers by Lin Cheng in
Google Scholar
PubMed
Search for other papers by Qiong Luo in
Google Scholar
PubMed
Department of Pathology, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, People’s Republic of China
Search for other papers by Zhiyan Liu in
Google Scholar
PubMed
Search for other papers by Zhongwei Lv in
Google Scholar
PubMed
Search for other papers by Libo Chen in
Google Scholar
PubMed
therapy, differentiation therapy, and immunotherapy are primarily used for thyroid carcinomas poorly controlled by traditional treatment, although most of the relevant researches remain ongoing. Molecular targeted therapy Inhibiting angiogenesis and
Search for other papers by Susanne Neumann in
Google Scholar
PubMed
Search for other papers by Christine C. Krieger in
Google Scholar
PubMed
Search for other papers by Marvin C. Gershengorn in
Google Scholar
PubMed
’s clinical activity score and exophthalmos was observed [ 24 ]. K1–70 is a promising treatment option and currently in phase I clinical trials (https://Clinical Trials.gov/show/NCT02904330) [ 25 ]. Recently, antigen-specific immunotherapies have been
Search for other papers by Earn H. Gan in
Google Scholar
PubMed
Search for other papers by Anna L. Mitchell in
Google Scholar
PubMed
Search for other papers by Ruth Plummer in
Google Scholar
PubMed
Search for other papers by Simon Pearce in
Google Scholar
PubMed
Search for other papers by Petros Perros in
Google Scholar
PubMed
What Is Known about This Topic? Anti-CTLA-4 immunotherapy used in cancer treatment can cause thyroiditis and Graves disease. What Does This Case Report Add? Transient thyroiditis and Graves disease usually take place within
Search for other papers by Jaume Capdevila in
Google Scholar
PubMed
Search for other papers by Desiree’ Deandreis in
Google Scholar
PubMed
Search for other papers by Cosimo Durante in
Google Scholar
PubMed
Search for other papers by Sophie Leboulleux in
Google Scholar
PubMed
Search for other papers by Markus Luster in
Google Scholar
PubMed
Search for other papers by Romana Netea-Maier in
Google Scholar
PubMed
Search for other papers by Kate Newbold in
Google Scholar
PubMed
Search for other papers by Susanne Singer in
Google Scholar
PubMed
Search for other papers by Gerasimos P Sykiotis in
Google Scholar
PubMed
Search for other papers by Beate Bartes in
Google Scholar
PubMed
Search for other papers by Kate Farnell in
Google Scholar
PubMed
Department of Internal Medicine and Therapeutics, University of Pavia, Italy
Search for other papers by Laura Deborah Locati in
Google Scholar
PubMed
patients with DTC treated with lenvatinib. Even though the therapeutic landscape in RAI-R DTC is evolving, with new targeted therapies, immunotherapy, etc., lenvatinib is expected to remain a first-line treatment and mainstay of therapy for several years in
Search for other papers by Pauline Campredon in
Google Scholar
PubMed
Multidisciplinary Thyroid Eye Consultation, Department of Endocrinology, Larrey University Hospital, Toulouse, France
Search for other papers by Philippe Imbert in
Google Scholar
PubMed
Search for other papers by Céline Mouly in
Google Scholar
PubMed
Search for other papers by Solange Grunenwald in
Google Scholar
PubMed
Search for other papers by Julien Mazières in
Google Scholar
PubMed
Search for other papers by Philippe Caron in
Google Scholar
PubMed
What Is Known about This Topic? Anti-PD-1 monoclonal antibody therapy is associated with immune-related adverse events, and the most frequent is inflammatory thyroiditis. During immunotherapy, immune-related ocular toxicities are
University of Lille, Lille, France
Search for other papers by Hippolyte Dupuis in
Google Scholar
PubMed
Search for other papers by Emilie Merlen in
Google Scholar
PubMed
University of Lille, Lille, France
Search for other papers by Arnaud Jannin in
Google Scholar
PubMed
Department of Dermatology, Lille University Hospital, Lille, France
Search for other papers by Philippe Jamme in
Google Scholar
PubMed
Search for other papers by Alexandre Fagart in
Google Scholar
PubMed
University of Lille, Lille, France
Search for other papers by Marie-Christine Vantyghem in
Google Scholar
PubMed
Search for other papers by Miriam Ladsous in
Google Scholar
PubMed
.1056/NEJMoa1709030 ) 2 Antonelli A Ferrari SM Fallahi P . Current and future immunotherapies for thyroid cancer . Expert Review of Anticancer Therapy 2018 18 149 – 159 . ( https://doi.org/10.1080/14737140.2018.1417845 ) 3 Illouz F Drui D Caron
Search for other papers by Alessandro Brancatella in
Google Scholar
PubMed
Search for other papers by Nicola Viola in
Google Scholar
PubMed
Search for other papers by Sandra Brogioni in
Google Scholar
PubMed
Search for other papers by Lucia Montanelli in
Google Scholar
PubMed
Search for other papers by Chiara Sardella in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Claudio Marcocci in
Google Scholar
PubMed
Search for other papers by Isabella Lupi in
Google Scholar
PubMed
Search for other papers by Francesco Latrofa in
Google Scholar
PubMed
autoimmune hyperthyroidism and Graves’ ophthalmopathy. Of note, euthyroid Graves’ ophthalmopathy is very uncommon after other immunotherapy drugs (e.g., interferon and alemtuzumab); in these settings, ophthalmopathy is usually associated with hyperthyroidism